Skip to content

Clinical trials

Mitral Valve Insufficiency trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mitral Valve Insufficiency Country / region: China Clear all

45 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20121
20161
20172
20192
20202
20216
20229
20234
20246
20258
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting19
Unknown status13
Not yet recruiting6
Completed5
Active, not recruiting2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
China National Center for Cardiovascular Diseases6
Beijing Anzhen Hospital4
Shanghai NewMed Medical Co., Ltd.3
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3
Sun Yat-sen University3
Xiang Wei3
Chinese Academy of Medical Sciences, Fuwai Hospital2
Hangzhou Valgen Medtech Co., Ltd2
Mitrassist Lifesciences Limited Co., Ltd.2
Pan Xiangbin2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mitral Valve Insufficiency45
Aortic Valve Insufficiency3
Atrial Fibrillation3
Cardiovascular Diseases3
Heart Defects, Congenital3
Mitral Valve Stenosis3
Tricuspid Valve Insufficiency3
Aortic Valve Stenosis2
Cardiomyopathy, Hypertrophic2
Embolism and Thrombosis2

Trials

Showing 76 to 45 of 45. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.